We are live on !
Find out more
Bronte Capital Management Portfolio holdings
AUM
$931M
Turnover
39.13%
1-Year Est. Return
47.97%
This Fund
S&P 500
This Quarter Est. Return
+8.4%
1 Year Est. Return
+47.97%
3 Year Est. Return
+122.73%
5 Year Est. Return
+132.88%
10 Year Est. Return
–
AUM
$931M
AUM Growth
-$78.8M
(-7.8%)
Cap. Flow
-$108M
Cap. Flow % of AUM
Cap. Flow %
-11.56%
Top 10 Holdings %
Top 10 Hldgs %
71.82%
Holding
69
New
15
Increased
8
Reduced
33
Closed
12
Avg Time Held
Equity + Options
1.9
years
Top 10 Avg Time Held
Equity + Options
3.4
years
Top 20 Avg Time Held
Equity + Options
2.8
years
Avg Time Held Equity only
1.9
years
Top 10 Avg Time Held Equity only
3.4
years
Top 20 Avg Time Held Equity only
3.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walt Disney
DIS
|
+$17.8M |
| 2 |
Brown-Forman Class B
BF.B
|
+$12.5M |
| 3 |
iShares Core S&P Small-Cap ETF
IJR
|
+$3.16M |
| 4 |
Revolution Medicines
RVMD
|
+$2.74M |
| 5 |
Tyler Technologies
TYL
|
+$2.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Interactive Brokers
IBKR
|
+$33.1M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$27.5M |
| 3 |
iShares Russell 2000 Growth ETF
IWO
|
+$11.8M |
| 4 |
Herbalife
HLF
|
+$8.5M |
| 5 |
Pinterest
PINS
|
+$7.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 23.01% |
| 2 | Miscellaneous | 17.74% |
| 3 | Communication Services | 15.44% |
| 4 | Healthcare | 13.95% |
| 5 | Consumer Staples | 10.99% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Turning Point Brands
TPB
$1.32B
| $3.45M | 0.37% |
40,721
-2,138
| -5% | -$177K |
2025 Q4
2 quarters
|
|
|
27
iShares Core S&P Small-Cap ETF
IJR
$103B
| $3.41M | 0.37% |
+23,004
| New | +$3.16M |
2026 Q2
0 quarters
|
|
28
Bath & Body Works
BBWI
$4.31B
| $3.33M | 0.36% |
143,800
-11,708
| -8% | -$224K |
2021 Q3
19 quarters
|
|
29
Mondelez International
MDLZ
$83.6B
| $3.08M | 0.33% |
53,234
-2,740
| -5% | -$165K |
2021 Q2
20 quarters
|
|
30
Riskified
RSKD
$1.13B
| $2.96M | 0.32% |
588,251
+99,770
| +20% | +$465K |
2022 Q3
15 quarters
|
|
31
Brown-Forman Class A
BF.A
$14.4B
| $2.61M | 0.28% |
95,365
-4,989
| -5% | -$137K |
2026 Q1
1 quarter
|
|
|
32
Tyler Technologies
TYL
$16.7B
| $2.43M | 0.26% |
+8,302
| New | +$2.62M |
2026 Q2
0 quarters
|
|
33
Paylocity
PCTY
$9.03B
| $1.87M | 0.2% |
17,874
-18,737
| -51% | -$2M |
2026 Q1
1 quarter
|
|
34
Nice
NICE
$5.52B
| $1.49M | 0.16% |
16,396
-695
| -4% | -$67.4K |
2025 Q4
2 quarters
|
|
35
Universal Display
OLED
$3.98B
| $889K | 0.1% |
10,269
-852
| -8% | -$78.6K |
2025 Q4
2 quarters
|
|
36
Verisk Analytics
VRSK
$26.2B
| $481K | 0.05% |
2,682
-220
| -8% | -$38.7K |
2026 Q1
1 quarter
|
|
37
Enovix
ENVX
$606M
| $92.9K | 0.01% |
41,765
+30,215
| +262% | +$200K |
2025 Q3
3 quarters
|
|
38
Treace Medical Concepts
TMCI
$262M
| $62K | 0.01% |
+15,577
| New | +$42.8K |
2026 Q2
0 quarters
|
|
39
Fate Therapeutics
FATE
$223M
| $58.7K | 0.01% |
21,740
-1,113
| -5% | -$2.06K |
2025 Q4
2 quarters
|
|
40
AN2 Therapeutics
ANTX
$151M
| $52.7K | 0.01% |
+10,895
| New | +$46.9K |
2026 Q2
0 quarters
|
|
41
C4 Therapeutics
CCCC
$407M
| $48.3K | 0.01% |
10,349
+316
| +3% | +$1.08K |
2025 Q4
2 quarters
|
|
42
ALX Oncology
ALXO
$160M
| $37.5K | ﹤0.01% |
+18,095
| New | +$32.4K |
2026 Q2
0 quarters
|
|
43
Blend Labs
BLND
$234M
| $32.9K | ﹤0.01% |
+19,247
| New | +$30.7K |
2026 Q2
0 quarters
|
|
44
PepGen
PEPG
$171M
| $32K | ﹤0.01% |
+17,776
| New | +$28.9K |
2026 Q2
0 quarters
|
|
45
Commerce.com Inc Series 1
CMRC
$302M
| $30.4K | ﹤0.01% |
+10,278
| New | +$29.4K |
2026 Q2
0 quarters
|
|
46
Pacific Biosciences
PACB
$699M
| $30K | ﹤0.01% |
+17,881
| New | +$26K |
2026 Q2
0 quarters
|
|
47
Acumen Pharmaceuticals
ABOS
$16.2M
| $28.6K | ﹤0.01% |
+10,716
| New | +$26.5K |
2026 Q2
0 quarters
|
|
48
Seer Inc
SEER
$90.3M
| $25.1K | ﹤0.01% |
+15,109
| New | +$27.4K |
2026 Q2
0 quarters
|
|
49
Alector
ALEC
$341M
| $23.6K | ﹤0.01% |
11,758
-7,524
| -39% | -$16.1K |
2025 Q4
2 quarters
|
|
50
NovaBridge Biosciences American Depositary Shares
NBP
$105M
| $21.8K | ﹤0.01% |
+11,192
| New | +$22.8K |
2026 Q2
0 quarters
|
|
Similar funds
AG
ACM
Bronte Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Bronte Capital Management held 69 positions worth $931M, down 7.8% from $1.01B the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Bronte Capital Management withdrew a net $108M in Q2 2026, closing 12 positions and reducing 33 holdings. Its most notable exit was iShares Russell 2000 Growth ETF, an estimated $11.8M position sold in full.
By sector, the portfolio is most concentrated in Financials at 23% of assets, up from 23% a quarter earlier, followed by Miscellaneous and Communication Services.
Against the trend, Bronte Capital Management opened a new position in Brown-Forman Class B worth $12.4M.
- Bronte Capital Management's largest Q2 2026 buy was Brown-Forman Class B: 464,313 shares worth $12.4M.
- Bronte Capital Management added most to Walt Disney in Q2 2026, an estimated $17.8M increase.
- Bronte Capital Management's biggest Q2 2026 reduction was Interactive Brokers, cutting an estimated $33.1M.
- Bronte Capital Management fully exited iShares Russell 2000 Growth ETF in Q2 2026, selling an estimated $11.8M.
- Bronte Capital Management's ten largest holdings make up 72% of its $931M portfolio in Q2 2026.
- Bronte Capital Management opened 15 new positions and closed 12 in Q2 2026.
- Bronte Capital Management's portfolio value fell 7.8% quarter-over-quarter to $931M.
Based on Bronte Capital Management's 13F filing for Q2 2026, filed 5 Aug 2026.